News

The e-methanol plant, built by European Energy & Mitsui, will supply companies including Maersk, LEGO & Novo Nordisk with ...
It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—heads for the exit. Under a mutual ...
May 16 - Novo Nordisk (NYSE:NVO) said CEO Lars Fruergaard Jrgensen will step down after eight years at the helm, following a sharp decline in its share price over the past year. Shares of the ...
Novo Nordisk A/S’ CEO exit raises governance questions, but continuity through internal succession likely limits strategic disruption. Valuation reset (~16.5x forward non-GAAP P/E) vs. LLY (~30x ...
Mads Claus Rasmussen / Ritzau Scanpix / AFP / Getty Images U.S.-listed shares of Novo Nordisk (NVO) declined in the opening minutes of trading Friday on the surprise news that CEO Lars Fruergaard ...
Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen is stepping down after eight years in the role, during which he led the company to an all-time high in the markets. Despite being the first to ...
Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...
Novo Nordisk, the maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by "mutual agreement" with the company's board of directors, citing "recent market challenges ...
Novo Nordisk A/S is replacing Chief Executive Officer Lars Fruergaard Jorgensen as the drugmaker wrestles with increased competition for its Wegovy obesity shots that transformed the weight-loss ...
COPENHAGEN (Reuters) - Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly ...
Wegovy and Ozempic-maker Novo Nordisk said today its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity ...